2023
Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States
Ito S, Potnis K, Allen C, Richmond R, Waldron C, Viswanathan G, Bona R, Goshua G. Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States. Blood 2023, 142: 492. DOI: 10.1182/blood-2023-190420.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioSevere hemophilia A.Quality-adjusted life expectancySevere haemophilia AHemophilia AFactor VIIIDistributional cost-effectiveness analysisHemophilia A.Chronic arthropathyOpen-label multicenter studyCoagulation factor replacementLifelong prophylactic treatmentCare of patientsCost-effectiveness ratioUSD/QALYProbabilistic sensitivity analysesCost-effectiveness analysisPackage insert informationDeterministic sensitivity analysesWeekly prophylaxisPrimary outcomeSecondary outcomesWeekly dosingFactor replacementIntracranial hemorrhage
2003
Recurrence of bipolar disorders and major depression
Angst J, Gamma A, Sellaro R, Lavori PW, Zhang H. Recurrence of bipolar disorders and major depression. European Archives Of Psychiatry And Clinical Neuroscience 2003, 253: 236-240. PMID: 14504992, DOI: 10.1007/s00406-003-0437-2.Peer-Reviewed Original ResearchConceptsRecurrence riskBipolar disorderDepressive disorderMajor depressionLifelong prophylactic treatmentRisk of recurrenceState of remissionMajor depressive disorderHigh recurrence riskLong-term trialsProphylactic treatmentDepressive patientsNew episodesBipolar IIRecurrenceSevere typeBP-IIDisordersSignificant gender differencesDepressionRiskGender differencesConstant riskHospitalisationRemission
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply